Let there Belite: the prospect of an oral pill for vision loss
Read on Onyx Newsroom →London Biopharma Summit 2026
Put Your Brand at the Centre of Biopharma’s Biggest Conversation
On 15–16 November 2026, 300+ biotech executives, investors, and key opinion leaders will gather 34 floors up in The Shard, London, for two days of deal-making, keynotes, and high-impact networking. Sponsorship puts your company at the heart of it all.
Why Sponsor the Summit?
An unrivalled opportunity to connect with biopharma decision-makers
Executive Audience
40% C-suite and VP-level biopharma executives, 10% founders, 30% service providers and suppliers, 10% government and regulators, 5% journalists, 5% academia. Every conversation matters.
Global Media Reach
Sponsor brands receive prominent placement in pre- and post-event editorial coverage across Onyx's digital channels and partner network.
Premium Positioning
Logo visibility on stage, in the delegate pack, on name badges, and across digital channels. Your brand woven into the fabric of the event from first impression to final handshake.
Speaking Opportunities
Select packages include keynote slots, fireside chat appearances, and panel moderation — putting your leadership front and centre before the audience that matters most.
Iconic Venue
The Shard, London — Western Europe’s tallest building. Private event floors with panoramic views. An unforgettable setting that elevates every brand associated with it.
Year-Round Visibility
Sponsorship isn’t just two days. Your logo and features live on across Onyx Newsroom, reaching our readership of biotech professionals 365 days a year.
Sponsorship Opportunities
Contact Lewis Hart, Event Manager, to discuss partnership packages and sponsorship opportunities.
lewis@onyxnewsroom.com
Belite Bio is a clinical-stage biopharmaceutical company developing novel oral therapies for retinal diseases, including Stargardt disease and geographic atrophy.
Their lead candidate, tinlarebant (LBS-008), is a once-daily oral RBP4 antagonist designed to reduce the accumulation of toxic vitamin A byproducts in the retina — offering a first-in-class approach to slowing or preventing vision loss in millions of patients worldwide.
Affinia Therapeutics is a clinical-stage biotechnology company pioneering rationally designed adeno-associated virus (AAV) vectors to unlock the full potential of gene therapy.
By engineering next-generation capsids with improved tissue targeting and reduced immunogenicity, Affinia is developing transformative one-time treatments for serious neurological and other genetic diseases.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.
Their liquid biopsy platform, Guardant360, analyses circulating tumour DNA from a simple blood draw, enabling clinicians to detect cancer earlier, guide treatment selection, and monitor response — fundamentally changing how cancer is managed.
Cellares is the first integrated development and manufacturing organisation (IDMO) for cell therapies, building the Cell Shuttle — a fully automated, end-to-end manufacturing platform.
By automating the entire cell therapy manufacturing workflow, Cellares aims to dramatically reduce costs, increase throughput, and make life-saving cell therapies accessible to every patient who needs them.
Avidity Biosciences is a clinical-stage biotechnology company and one of the fastest-growing biotechs in history, pioneering a new class of RNA therapeutics — antibody-oligonucleotide conjugates (AOCs).
By combining the targeting precision of monoclonal antibodies with the gene-silencing power of oligonucleotides, Avidity is developing treatments for serious muscle diseases including myotonic dystrophy and facioscapulohumeral muscular dystrophy.
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercialising novel treatments for gastrointestinal diseases.
Their lead product, vonoprazan, is the first major innovation in acid-related disorders in over three decades. Now FDA-approved, it offers faster, more potent acid suppression than traditional proton pump inhibitors for millions of patients suffering from GERD and related conditions.
ImmunityBio is a commercial-stage immunotherapy company developing next-generation therapies that activate the body’s own immune system to fight cancer.
Their FDA-approved ANKTIVA platform harnesses natural killer (NK) cells and T cells to target and destroy tumours. With a growing pipeline across bladder cancer, pancreatic cancer, and other solid tumours, ImmunityBio is pioneering a new era of immunology-driven oncology treatment.
Ocugen is a biotechnology company focused on discovering, developing, and commercialising gene therapies to cure blindness diseases and developing biologics to address unmet needs in oncology and infectious diseases.
Their lead programme, OCU400, is a modifier gene therapy designed to be a single, broad-spectrum treatment for multiple forms of inherited retinal dystrophies — potentially offering a cure for conditions that currently have no treatment options.
Verily, an Alphabet company, is a precision health platform combining advanced technology with life sciences expertise to generate actionable health insights at scale.
From clinical research tools and real-world evidence platforms to population health analytics, Verily is building the data infrastructure that pharmaceutical companies, health systems, and researchers need to accelerate the development of better health outcomes.
MassBio is the trade association for Massachusetts’s life sciences supercluster — the most innovative square mile in the world, home to over 1,000 biopharma companies.
Representing start-ups, mid-caps, and global leaders alike, MassBio drives policy, forges industry connections, and champions the ecosystem that continues to produce a disproportionate share of the world’s breakthrough medicines.
With support from
CEO Interviews